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Introduction: Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by 
systemic joint inflammation that often leads to significant disability. Several effective anti-
TNF agents have been used, but some patients have shown an inadequate response. Ritux-
imab is a therapeutic monoclonal antibody indicated in such cases.
Methods: We conducted a systematic review to access efficacy and safety of rituximab in 
patients with active RA which have or have not been treated with anti-TNF agents before, 
and to relate outcome with RF and anti-CCP serology. We searched major electronics data-
bases, grey literature and searched for references manually. We used Review Manager®5.1 
for meta-analysis.
Results: We included six RCTs comparing rituximab 1000 mg with placebo. Methotrexate 
was used by both groups. Treatment with rituximab was more effective in naïve and in 
anti-TNF treatment failure patients - ACR20/50/70 and EULAR response. We observed lower 
changes in Total Genant-modified Sharp score, erosion score and joint narrowing scores in 
the rituximab group, and SF-36, FACIT-T and HAQ-DI scores were also better in this group. 
There were no differences between groups regarding safety outcomes, with exception of 
acute injection reactions, which were more common on rituximab group. More RF/anti-CCP 
seropositive patients achieved ACR20 than RF/anti-CP negative patients in rituximab group.
Conclusion: Available data support the use of rituximab for the treatment of RA, as it is an 
effective and safe option for naïve and anti-TNF treatment failure patients. RF and anti-CCP 
seam to influence treatment results, but this inference needs further research.
© 2014 Sociedade Brasileira de Reumatologia. Published by Elsevier Editora Ltda. 
All rights reserved.
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Rituximabe para o tratamento da artrite reumatoide: revisão sistemática
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Introdução: A artrite reumatoide (AR) é uma doença autoimune crônica caracterizada por 
inflamação articular sistêmica que, com frequência, leva a significativa incapacitação. Vá-
rios agentes anti-TNF têm sido usados efetivamente, mas alguns pacientes demonstraram 
resposta inadequada. Rituximabe é um anticorpo monoclonal terapêutico indicado em tais 
casos.
Métodos: Realizou-se uma revisão sistemática para avaliar a eficácia e a segurança de ritu-
ximabe em pacientes com AR ativa previamente tratados ou não com agentes anti-TNF e 
para relacionar o desfecho com a sorologia para FR e anti-CCP. Pesquisaram-se importantes 
bancos de dados eletrônicos e a literatura não convencional, além de se fazer uma busca 
manual de referências. Para a meta-análise, utilizou-se o programa Review Manager® 5.1.
Resultados: Consideramos seis ERCs comparando rituximabe 1000 mg com placebo. Em am-
bos os grupos usou-se Metotrexato. O tratamento com rituximabe foi mais efetivo em pa-
cientes jamais tratados e nos que não obtiveram sucesso com a terapia anti-TNF – critérios 
ACR 20/50/70 e EULAR. No grupo de rituximabe, observaram-se mudanças menos expressi-
vas nos escores de Sharp/Genant, de erosão e de estreitamento do espaço articular; nesse 
grupo, os escores SF-36, FACIT-T e HAQ-DI também foram melhores. Não foram notadas 
diferenças entre grupos com relação aos desfechos de segurança, com exceção das reações 
agudas à infusão, que foram mais comuns no grupo de rituximabe. Ainda no grupo de ri-
tuximabe, um número maior de pacientes soropositivos para FR/anti-CCP alcançou ACR20, 
em comparação com pacientes negativos para RF/anti-CCP.
Conclusão: Os dados disponíveis falam em favor do uso de rituximabe para o tratamento 
da AR, como opção efetiva e segura para pacientes jamais tratados ou que não obtiveram 
sucesso com o tratamento anti-TNF. FR e anti-CCP parecem influenciar os resultados do 
tratamento, mas essa inferência ainda está à espera de futuras pesquisas.
© 2014 Sociedade Brasileira de Reumatologia. Publicado por Elsevier Editora Ltda. 
Todos os direitos reservados.
Introduction
Rheumatoid arthritis (RA) is a systemic autoimmune dis-
ease characterized by symmetrical joint inflammation that 
often evolves into erosive joint damage.1-3 Its prevalence 
and incidence vary among countries, affecting 2% of Argen-
tina’s population and over 10% of the U.S. population.4 In 
addition to the articular manifestations, which can lead to 
damage and functional disability, the disease is related to 
systemic manifestations and an increase in cardiovascular 
mortality.5
The development of anti-TNF monoclonal antibodies shed 
light on the treatment of those patients who have failed the 
first-line therapy, in which synthetic disease modifying drugs 
(DMD) such as methotrexate (MTX), sulfasalazine and leflu-
nomide are used.6-8 However, after one year of treatment, ap-
proximately 20% of patients abandoned treatment with anti-
TNF due to its ineffectiveness.9 To work around this situation, 
the use of a different therapeutic target is an interesting al-
ternative.
Rituximab is a monoclonal antibody that selectively de-
pletes peripheral CD20+ B cells. Evidence supports its use in 
combination with MTX in patients who have failed anti-TNF 
therapy and in those naïve to treatment with these agents.10-13 
However, the patients’ response may be incomplete, indicat-
ing the necessity to investigate biomarkers that have predic-
tive or prognostic value, to assist in choosing the best treat-
ment strategy. Rheumatoid factor (RF) is an IgM antibody 
targeted to the constant region of IgG. The anti-cyclic citrul-
linated peptide (anti-CCP) antibody has more specificity for 
RA, relating to a more aggressive disease. Both markers are 
used for the diagnosis of RA and its titration corresponds to 
the disease activity.14 
The objectives of this review were to evaluate the safety 
and efficacy data of rituximab, as well as to illustrate the in-
fluence of RF and anti-CCP in the outcome of treatment of 
patients with active RA.
Methods
This systematic review (SR) is part of a larger trial that also 
includes infliximab, adalimumab and etanercept, designed to 
evaluate the efficacy and safety of these agents in the treat-
ment of RA. We conducted this trial according to the Cochrane 
handbook15 and prepared the manuscript using PRISMA State-
ment as reporting guidance.16
Eligibility criteria 
Randomized controlled trials (RCTs) comparing a scheme 
with rituximab versus without rituximab in the treatment of 
RA in patients over 18 years of age were eligible. We excluded 
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trials with less than a total of 30 participants, pilot trials and 
dosage comparison.
Search for trials 
We investigated the databases EMBASE (until April 2012), Co-
chrane Register of Controlled Trials (CENTRAL; until June 2012), 
MEDLINE (via PubMed; until July 2012) and LILACS (until Octo-
ber 2012) in order to to identify potentially eligible articles in 
English, Spanish or Portuguese languages. For manual search 
we investigated meetings’ annals (American College of Rheu-
matology, 2010 and 2011; European League Against Rheuma-
tism, 2010, 2011 and 2012) dissertations and theses’ banks 
(OpenThesis, National Library of Australia – Trove, Biblioteca 
Digital Brasileira de Teses e Dissertações from USP, Theses Da-
tabase of Capes, Pro Quest Dissertation & Theses Database) and 
reference lists of articles included in other SRs. We searched 
ongoing trials and unpublished trials in the databases of Clini-
calTrials.gov and EUClinical Trials Register records.
Outcome measurements 
We considered as primary outcome measures: ACR20, ACR50 
and ACR70.17 The secondary outcome measures were EULAR 
responses,18 individual components of ACR, disease activity 
measured by baseline DAS28-ESR change, SF-36 scores,19,20 fa-
tigue assessed by FACIT-F21 and adverse events (AE) .
Study selection and data extraction 
We performed the assessment of the eligibility of the trial and 
data collection, in a standard form, in duplicate and, when 
necessary, a third reviewer solved disagreements. Authors of 
the papers were contacted when there was any difficulty in 
extracting data. We organized the trials according to the pre-
vious use of DMD.
Quality assessment and risk of bias of included trials 
We assessed the methodological quality using the modified 
Jadad scale22 and the risk of bias by Cochrane Collaboration 
tool.23 The trial was considered high risk if presented a pos-
sibility of high risk of bias in at least one of the criteria evalu-
ated. We calculated the interobserver agreement using Kappa 
statistics24 using SPSS® 17 software, which we considered 
excellent for Jadad scale; Kappa = 0.83 ± 0.60 (SD), and sub-
stantial for assessing risk bias; Kappa = 0.71 ± 0.69. We also 
checked conflicts of interest declared by authors of the in-
cluded articles.
Statistical analysis 
We used the Review Manager® 5.1 software to conduct the 
meta-analyses using the random effects model and consid-
ered those analyses with I2 > 40% and P value of chi-squared 
test < 0.10 with substantial heterogeneity.25 The causes of het-
erogeneity were investigated by the exclusion of one trial at a 
time and subsequent verification of the change in the values 
of I2 and P. For dichotomous outcomes, we used the relative 
risk (RR) with confidence interval (CI) of 95% and standard 
deviation as a measure of association. Continuous outcomes 
were qualitatively evaluated and presented as mean ± SD. 
We planned subgroup analyses considering seropositivity for 
RF and anti-CCP and developed a sensitivity analysis using 
participant type for primary outcomes. We assessed meta-
analyses’ publication bias by funnel chart.
Results
Results of the Search
After review by title and abstract, 249 references for ritux-
imab, infliximab, adalimumab and etanercept were consid-
ered eligible. Six RCTs were enrolled on rituximab, comprising 
15 published articles (Fig. 1). 
Result of Search: 5782
PubMed: 3620
Lilacs: 98
Embase: 1577
Central: 487
Total of excluded articles by title: 2648
Reason for exclusion:
Excluded by trial type: 1123
Excluded by participant type: 283
Excluded by intervention type: 135
Excluded by outcome type: 1107
Total of articles excluded by abstract: 
1912
Reason for exclusion:
Excluded by trial type: 1366
Excluded by participant type: 79
Excluded by intervention type: 83
Excluded by outcome type: 384
Total of articles excluded by complete 
text: 175
Reason for exclusion:
Excluded by trial type: 96
Excluded by participant type: 02
Excluded by intervention type: 13
Excluded by outcome type: 24
Not found: 40
Total of included articles by complete 
text: 74
Adalimumab: 17
Infliximab: 17
Etanercept: 31
Rituximab: 15
Manual Search: 9
Duplicates: 92
Total of included articles 
after removal of 
duplicates: 5699
Total of articles included 
by title: 3051
Total of articles included 
by abstract: 1139
Total of RCT articles 
included by abstract: 249
Articles of observational trials that will be 
analysed in a subsequent phase: 890
Total of included articles in 
searchs: 5791
Fig. 1 – Flowchart of selection of trials.
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We included 15 trials in progress, and one of them was ter-
minated prematurely in some research centres without stated 
justification (2008-002381-55). A trial was completed, but we 
could not find the publication of the results (NCT01117129). 
We did not include any dissertation or thesis.
Trial characteristics 
The characteristics of RCTs included are shown in Table 1. 
We evaluated a total of 2,139 patients with active disease, of 
which 1,198 used rituximab 1,000 mg twice with an interval 
of 15 days. MTX was used as co-treatment for all patients. The 
participants averaged 50 years of age, and 80% were female. 
The inclusion criteria of the trials were similar in terms of the 
diagnostic criteria – all followed the classification criteria of 
the American College of Rheumatology (ACR).26
One trial evaluated outcomes in 52 and 104 weeks of MTX 
naïve participants who had, on average, less than one year 
of diagnosis.27-29 The baseline data of participants in this trial 
were similar to those in the other trials, with the exception of 
the radiographic score, much lower in those newly diagnosed 
patients. In the other five trials, the participants had active dis-
ease despite MTX use and averaged more than seven years of 
disease evolution. In two trials, the participants were naïve for 
anti-TNF, while the outcomes were presented for 24,30 48 and 
104 weeks.31-34 In the other three trials, the participants exhib-
ited treatment failure with anti-TNF agent, while the outcomes 
were presented after 24 weeks of follow-up (Table 1).35-41
One trial evaluated the effectiveness of the second admin-
istration of rituximab in patients in whom the first applica-
tion cycle was not sufficient to achieve remission, i.e., DAS28-
ESR < 2.6.41 In this trial, all participants received rituximab in 
an open phase. After 24 weeks of follow-up, those patients 
who did not achieve remission were randomized to receive 
re-treatment with rituximab or placebo and were followed for 
another 24 weeks. We considered the results of this part of the 
trial in the meta-analyses.
Assessment of methodological quality and risk of bias 
All included trials had high methodological quality (Jadad 
score, modified = 5). The risk of bias assessment showed that 
the methods of generation of allocation sequence and of en-
suring allocation confidentiality were considered adequate in 
only one RCT.27-29 For the remaining domains, all trials had low 
risk of bias (Fig. 2).
Conflicts of interest and publication bias 
All included trials were funded by the pharmaceutical indus-
try and only one report36 did not declare a conflict of interests. 
The funnel plot suggested publication bias, but this analysis 
could not be considered robust, considering that the number 
of included trials was small.
Primary outcomes
The meta-analyses that evaluated ACR measures after 24 
weeks of treatment included studies whose participants were 
naïve or had failed with anti-TNF treatment (n = 1,640). In gen-
eral, more patients in rituximab group achieved ACR20, ACR50 
and ACR70 compared to placebo. However, these analyses 
showed substantial heterogeneity, and the subset of patients 
naïve to anti-TNF displayed a robust result. But it is notewor-
Table 1 – Summary of characteristics of included trials
Study N Women 
(%)
Age  
(years ± DP)
Disease 
duration 
(years ± DP)
Previous use of 
MMCD (others than 
MTX; no. ± DP)
Previous use of anti-TNF 
N (%) No. (DP)
MTX virgins
IMAGE [29-31]
placebo 249 77 48,1 (12,7) 0,91 (1,1) 30 -
rituximab 250 85 47,9 (13,3) 0,92 (1,3) 31 -
Anti-TNF virgins
Edwards [33-36]
placebo 40 80 54 (11) 11 (7) 2,6 (1,3) -
rituximab 40 75 54 (12) 12 (7) 2,5 (1,4) -
SERENE [32]
placebo 172 85,5 52,16 (12,390) 7,48 (7,642) 1,1 (1,10) -
rituximab 170 81,2 51,30 (12,644) 6,61 (7,294) 1,1 (1,11) -
Failure with Anti-TNF
DANCER [37,38]
placebo 122 79,5 50,8 (11,7) 9,6 (7,7) 2,2 27
rituximab 122 76,2 52,1 (10,9) 11,3 (8,5) 2,5 31,1
REFLEX [39-42]
placebo 201 82 52,89 (12,31) 11,74 (7,68) 2,4 (1,8) IFX: 81; ADA: 18; ETA: 50
rituximab 298 81 52,24 (12,20) 12,15 (8,4) 2,6 (1,8) IFX: 71; ADA: 23; ETA: 55
SUNRISE [43]
placebo 157 79 54 (11) 11 (8,5) 4,1 (1,9)* 1: 53; 2: 35; 3: 12†
rituximab 318 81 54 (11) 12 (9,2) 4,1 (2,0)* 1: 57; 2: 32; 3: 11
ADA adalimumab, ETA etanercepte, IFX infliximab
* Including anti-TNF, † 1, 2, 3 mean one, two and three agents anti-TNF, respectively.
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thy that this subgroup is small, n = 22; then, more studies are 
needed to confirm the result (Fig. 3). In the analyses of hetero-
geneity, it was noted that one trial reported favourable results 
with the use of rituximab, a statistically significant result, but 
less expressive than the other RCTs.41 After its exclusion of 
the meta-analyses, the results favouring the use of rituximab 
persisted, and the heterogeneity decreased to ACR20, ACR50 
and ACR70, respectively RR (95% IC) = 2.24 (1.86-2.69; I2 = 15 %; 
P = 0.32) , RR = 2.86 ( 2.07-3.94; I2 = 0%; P = 0.90) and RR = 3.91 
(1.84-8.31; I2 = 50%; P = 0.11). 
In the pooled analysis of two trials (n = 579), we did not 
perceive any benefits from the use of the biological agent 
compared to placebo for ACR20 until 48-52 weeks and 104 
weeks of follow-up.27-29,31-34 The ACR50 and ACR70 results did 
not favour the use of rituximab until 48-52 weeks, although 
they have favoured its use till 104 weeks. This fluctuation of 
the presence or absence of benefit may be related to the small 
number of participants. Furthermore, the type of patients in 
these two trials was different: one trial evaluated MTX-naïve 
patients with less than one year of disease evolution,29-31 and 
the other evaluated patients naïve to anti-TNF with more 
than ten years of diagnosis.31-34
Secondary outcomes
In general, the group of patients who used rituximab achieved 
a statistically significant improvement compared to placebo 
in all individual components of the ACR, including in relation 
to the average change in HAQ-DI score. The meta-analysis of 
the number of participants who showed a change in HAQ-DI 
score ≥ 0.22 after 24 weeks from baseline (n = 1,161) pointed 
to the benefit of rituximab use with substantial heterogene-
ity, probably due to the SERENE trial.30 The joint analysis of 
two trials (n = 562) showed no statistically significant differ-
ence between groups after 48-52 weeks. After 72 weeks, there 
was no difference between intervention and control groups 
of patients with more than ten years of diagnosis.31 But after 
104 weeks there was a difference which benefited the use of 
rituximab in patients with less than one year of disease pro-
gression (Table 2).27-29
After 24 weeks of follow-up, more patients in rituximab 
group compared to placebo achieved good (n = 1,637) and mod-
erate (n = 1,393) EULAR responses, but with substantial hetero-
geneity (data not shown). Regarding good EULAR response, in 
the analysis of heterogeneity (and after removal of the SERENE 
trial)30 the outcome continued favouring rituximab. The analysis 
of the trial that evaluated recently diagnosed patients showed 
that the benefit of rituximab remained after 52 and 104 weeks 
of follow up.27-29 The heterogeneity of good and moderate EU-
LAR responses diminished with the exclusion of those partici-
pants with therapeutic failure with anti-TNF,35,39 and with the 
exclusion of participants naïve to anti-TNF, respectively.30-34 The 
change of baseline DAS28-ESR was generally higher in ritux-
imab group compared to placebo after 24, 52 and 104 weeks of 
follow-up. A pooled analysis of two trials showed no difference 
between groups in relation to the outcomes of low activity of 
the disease and remission till 24 weeks of follow-up;30,41 how-
ever, more patients in rituximab group compared to placebo 
achieved these targets after 52 and 104 weeks in the trial that 
evaluated patients with less diagnosis time (Table 2).27-29
The summarized physical component (SPC) change of 
SF-36 was superior and statistically significant in rituximab 
group compared to placebo after 24 and 52 weeks of follow-
up. On the other hand, the results of the summarized mental 
component (SMC) change were divergent: two trials showed 
no difference between groups and other two showed a sta-
tistically significant difference. In joint analyses, the chances 
of achieving a mean change of SPC > approx. 5 and SMC > 
approx. 5 after 24 weeks of treatment were higher and sta-
tistically significant in participants who used rituximab. The 
heterogeneity of the first analysis was substantial, but the in-
dividual reports favoured rituximab (Table 2).
The group using rituximab had benefits with respect to the 
fatigue measured by FACIT-F, as compared to placebo after 24 
and 52 weeks of treatment. Likewise, the chance of achieving 
a clinically significant lower change after 24 weeks of treat-
ment, i.e., a mean change in FACIT-F score ≥ approx. 3.5, was 
higher in participants who used the biological agent (Table 2). 
Two trials reported that the participants using rituximab 
achieved better results in radiological outcomes than those in 
placebo.35-40 A joint analysis (n = 934) showed that the partici-
pants treated with the biological agent had lower probability 
of progression by the Sharp score (modified) compared to pla-
cebo + MTX after 104 weeks of treatment (Table 2).
Regarding safety, there was no difference between inter-
vention and control groups regarding the incidence of severe 
AEs, malignancies and death. Infection was the most common 
AE in the trials. In any case, the rate of occurrence of serious 
infections was low, about 2% after 24 months of treatment 
in both groups, increasing to approximately 6% after this pe-
Fig. 2 – Assessment of risk of bias using the Cochrane 
Collaboration tool. A. Graph of risk of bias of all trials 
included in this review, presented by author names of 
each trial and their respective percentages in each item 
of the assessment. B. Summary of risk of bias of the trials 
(represented by trial names) with their respective result in 
each item of assessment.
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Total events  115 55
Heterogeneity: Tau2 = 0.00; Chi2 = 0.19, df = 1 (P = 0.67); I2 = 0%
Test for overall effect Z = 5.70 (P < 0.00001)
Total events  390 141
Heterogeneity: Tau2 = 0.22; Chi2 = 23.54, df = 2 (P = 0.00001); I2 = 92%
Test for overall effect Z = 2.20 (P = 0.03)
Total (95% CI)  948  692  100.0%  1.92 [1.36, 2.73]
Total events  505 196
Heterogeneity: Tau2 = 0.13; Chi2 = 26.49, df = 4 (P = 0.00001); I2 = 85%
Test for overall effect Z = 3.66 (P = 0.0003)
Teste for subgroup differences: Chi2 = 0.15, de = 1 (P = 0.70). I2 = 0%
Total (95% CI)  948  692  100.0%  2.33 [1.35, 4.01]
Total events  221 83
Heterogeneity: Tau2 = 0.28; Chi2 = 17.97, df = 4 (P = 0.001); I2 = 78%
Test for overall effect Z = 3.05 (P = 0.002)
Test for subgroup differences: Chi2 = 0.70, de = 1 (P = 0.40). I2 = 0%
Total (95% CI)  948  692  100.0%  2.94 [1.30, 6.66]
Total events  131 39
Heterogeneity: Tau2 = 0.61; Chi2 = 16.70, df = 4 (P = 0.002); I2 = 76%
Test for overall effect Z = 2.58 (P < 0.010)
Test for subgroup differences: Chi2 = 0.22, de = 1 (P = 0.64). I2 = 0%
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Fig. 3 – Forest plot depicting the statistically significant difference between rituximab and placebo in response criteria of the 
American College of Rheumatology (ACR) after 24 weeks of treatment. A. ACR20 (20% of improvement). B. ACR50. C. ACR70.
riod. Acute reaction to the first infusion was more common in 
rituximab group compared to placebo. In the second infusion, 
we could observe an opposite association; more patients in 
placebo group exhibited a reaction. There were no deaths re-
lated to this outcome in the RCTs included (Table 2).
The loss for total follow-up was higher in placebo group 
compared to rituximab. Individually, the trials were differ-
ent as the magnitude of the loss, ranging from 2.5% to 14% 
in rituximab group and from 5% to 35% in placebo group. The 
losses due to lack of efficacy were more frequent in placebo 
group and the rates of loss due to AEs were not different be-
tween groups (Table 2).
Subgroup analysis – RF and anti-CCP 
With the exception of one trial that included only rheuma-
toid factor-positive (RF+) participants, the groups of other tri-
als were balanced with regard to the inclusion of positive and 
negative participants.31-34 These latter were always minority 
and were not included in the overall analysis of a trial.35,36 The 
distribution of patients in relation to anti-CCP was reported 
by a trial, with homogeneity between groups.41
With respect to ACR20, we could observe a smaller pro-
portion of responders in the FR- group when compared to 
FR+. We could also observe that in the group FR+ the number 
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Table 2 – Joint analysis of the secondary outcomes of efficacy, adverse events e loss of follow-up
Outcome Rituximab n Placebo n RR (95% IC) P Value I2 (%)
HAQ-DI < 0,22
24 weeks [32, 36, 37, 40] 629 532 1,61 (1,22, 2,12) 0,004 77
48-52  weeks [29, 36] 288 274 1,57 (0,71, 3,44) 0,02 82
72 weeks [36] 40 40 4,33 (1,34, 14,05) - -
104 weeks [31] 250 249 1,12 (1,03, 1,21) - -
Good EULAR response
24 weeks [32, 35, 37, 39, 43] 946 619 3,37 (1,35, 8,43) <0,0001 84
52 weeks [29] 250 249 2,32 (1,72, 3,14) - -
104 weeks [31] 250 249 2,10 (1,61, 2,72) - -
Moderate EULAR response
24 weeks [32, 33, 39, 43] 824 569 1,62 (1,10, 2,37) 0,0001 86
Low DAS 28 activity
24 weeks [32, 43] 488 329 1,61 (0,70, 3,72) 0,05 73
52 weeks [29] 250 249 2,13 (1,60, 2,84) - -
104 weeks [31] 250 249 1,93 (1,50, 2,48) - -
DAS 28 remission
24 weeks [32, 43] 488 329 2,05 (0,64, 6,53) 0,06 73
52 weeks [29] 250 249 2,40 (1,65, 3,48) - -
104 weeks [31] 250 249 2,49 (1,72, 3,61) - -
PCS (SF-36) ≥ ~5
24 weeks [32, 40] 468 373 2.48 (1.13, 5.46) 0,0009 91
52 weeks [29] 250 249 1.21 (1.08, 1.36) - -
MCS (SF-36) ≥ ~5
24 weeks [32, 40] 468 373 1,71 (1,36, 2,16) 0,53 0
52 weeks [29] 250 249 1,16 (0,98, 1,37) - -
FACIT-F ≥ ~3.5
24 weeks [37, 40] 420 322 1,90 (1,60, 2,25) 0,41 0
52 weeks [29] 250 249 1,11 (1,00, 1,25) - -
No progression at mTSS
24 weeks [29] 244 232 1,19 (1,04, 1,36) - -
52 weeks [29] 244 232 1,21 (1,03, 1,41) - -
96-104 weeks [31,42] 252 420 1,53 (1,29, 1,81) 0,84 0
No progression at erosion score
24 weeks [40] 268 177 1,10 (0,95, 1,28)
96-104 weeks [31,42] 514 420 1,50 (1,26, 1,78) 0,20 39
Serious adverse events
24 weeks [32, 33, 37, 39, 43] 1028 727 0,98 (0,70, 1,38) 0,44 0
48-52 weeks [29, 33] 290 289 0,93 (0,57, 1,52) 0,91 0
104 weeks [31] 250 249 0,78 (0,51, 1,19) - -
Serious infections
24 weeks [32, 33, 37, 43] 720 518 0,86 (0,36, 2,04) 0,74 0
48-52 weeks [29, 33] 290 289 0,68 (0,30, 1,57) 0,34 0
104 weeks [31] 250 249 0,63 (0,31, 1,27) - -
Reaction at the infusion site
1° infusion [29, 32, 33, 37, 39, 43] 1280 976 1,55 (1,30, 1,86) 0,42 0
2° infusion [29, 32, 37, 39, 43] 1238 936 0,79 (0,63, 0,99) 0,83 0
Losses of follow-up
24 weeks [32, 33, 37, 39, 43] 1030 727 0,47 (0,29, 0,76) 0,18 36
48-52 weeks [29, 33] 290 289 0,54 (0,04, 7,56) 0,0004 92
72 weeks [36] 40 40 0,48 (0,28, 0,82) - -
104 weeks [31, 36] 290 289 0,48 (0,28, 0,82) - -
Losses by lack of efficacy
24 weeks [33, 37] 232 189 0,27 (0,16, 0,45) 0,85 0
48-52 weeks [29, 33] 290 289 0,19 (0,08, 0,50) 0,74 0
72 weeks [37] 40 40 0,44 (0,15, 1,33) - -
104 weeks [36] 40 40 0,24 (0,09, 0,64) - -
Losses by AE
24 weeks [32, 33, 37, 39, 43] 1028 727 1,47 (0,53, 4,09) 0,15 41
48-52 weeks [29, 33] 290 289 0,95 (0,17, 5,34) 0,21 37
72 weeks [36] 40 40 0,33 (0,04, 3,07) - -
104 weeks [31, 36] 290 289 0,38 (0,17, 0,85) 0,67 0
AE Adverse events, DAS 28 Disease Activity Score 28-joint assessment for swelling and tenderness, EULAR European league Against Rheumatism, 
FACIT-F Functional Assessment of Chronic Illness Therapy – Fatigue, HAQ-DI Health Assessment Questionnaire – Disability Index, MCS Mental 
Component Summary, mTSS Mean change in Genant-modified Sharp radiographic score, PCS Physical Component Summary, SF-36 Medical 
Study Short-Form Health Survey.
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versus intervention group; however, these analyses were not 
statistically significant.
In SERENE trial,30 after 24 weeks of treatment (the con-
trolled trial phase) there was no difference in relation to the 
change in DAS28-ESR among patients FR+ and FR- who used 
rituximab. In the open phase of the trial (24 to 48 weeks of 
treatment), the patients who had not achieved remission 
were re-treated with the biological agent; more patients FR+ 
achieved ACR50 and ACR70, compared to patients FR-.
Discussion
The results of efficacy and safety of this RS point to the ben-
efit of rituximab 1000 mg applied twice at 15-day intervals as-
sociated with weekly MTX for the treatment of RA. Regarding 
the primary outcomes, greater number of patients achieved 
ACR20, ACR50 and ACR70 in rituximab group versus placebo. 
This result was obtained for up to 24 weeks of follow-up in pa-
tients naïve and in those patients who have failed with anti-
TNF and with more than seven years of the disease; and for 
up to 52 weeks for patients naïve to MTX and anti-TNF and 
newly diagnosed. These results can also be applied to good 
and moderate EULAR responses.
In comparison to individual components of ACR response 
criteria, summarized physical and mental components of SF-
36, fatigue measured by FACIT-F and in relation to the change 
in baseline DAS28-ESR, we noted better results with ritux-
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Fig. 4 – Forest-plot depicting the responses of the American College of Rheumatology ACR20 (20% improvement) of 
rituximab versus placebo. A. RF-positive patients. B. RF-negative patients.
of participants treated with rituximab achieved ACR20 that 
was statistically significant compared to placebo, but with 
substantial heterogeneity; RR = 1.71 (1.19-2.48; I2 = 90%; P < 
0.00001), and this was explained by the exclusion of any trial. 
In FR- group, there was no difference between experimental 
and control groups; however, the analysis also showed sub-
stantial heterogeneity; RR = 1.16 (0.73-1.85; I2 = 71%; P = 0.02), 
with no explanation (Fig. 4).
The IMAGE trial also assessed ACR50, ACR70, good EULAR 
response, low activity, and remission of disease according to 
DAS28-ESR, percentage of participants without radiological 
progression and mean change in modified Sharp score in re-
lation to seropositivity for RF and anti-CCP.27 After 52 weeks 
of follow-up, only the mean change in modified Sharp score 
was statistically different between rituximab and placebo in 
the analysis of participants FR+. In this trial, all participants 
FR- were anti-CCP-.
According to Tak et al.,29 after 104 weeks of follow-up the 
participants FR+ and/or anti-CCP+ in rituximab group had a 
higher probability of not showing radiological progression 
compared to placebo; odds ratio (OR, 95% CI) = 2.228 (1.513-
3.281).29 In the analyses of the participants FR- and anti-CCP-, 
rituximab group showed a tendency to higher probability of 
non-progression compared to placebo, but without statisti-
cal significance; OD = 1.833 (0.558-6.027). Regarding ACR50, 
the group differences were statistically significant in the sub-
group FR+ and/or anti-CCP+. The participants FR- and anti-
CCP- that used placebo achieved ACR50 in greater proportion 
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imab. Remission and low disease activity were reported by 
three trials, despite all other trials also measured disease ac-
tivity by DAS28-ESR.27,30,41 These measures were achieved after 
52 weeks of treatment for newly diagnosed patients.27
The prevention or minimization of the progression of joint 
damage is a mainstay RA treatment; however, only IMAGE27 
and REFLEX39 performed an analysis of radiographic progres-
sion, and in both trials the participants who used rituximab 
achieved better results versus placebo after 104 weeks. We 
need more trials to strengthen the results of radiographic 
progression.
In this review we observed that the favourable results with 
rituximab according to ACR were more expressive in the trial 
that studied patients with less than one year of diagnosis,27 
which confirms the recommendations of ACR7 and EULAR8 
current guidelines, pointing to the fact that the treatment of 
RA will be more effective if started early.
SUNRISE41 was responsible for high heterogeneity in vari-
ous analyses. In this trial, patients who did not achieve re-
mission with an application of rituximab were randomized 
to re-treatment from 24th week. This trial showed benefits 
of rituximab versus placebo in all parameters measured, but 
the results were less significant than those shown by the 
other included trials. The authors reported that patients who 
achieved ACR20, ACR50 and ACR70 after the first application 
of rituximab were more likely to maintain its gains or improve 
with re-treatment with rituximab. On the other hand, pa-
tients who did not achieve such measures were not benefited 
with the second drug application.
Emery et al.42 conducted a joint analysis of three RCTs and 
its extensions – SERENE30 and MIRROR,43 with 43 participants 
re-treated to achieve clinical remission (Treat to Target – TT) 
(n = 236), and DANCER,35 and patients re-treated when nec-
essary (RWN) (n = 257). The groups were homogeneous with 
respect to basal data, with the exception of disease duration, 
that was 3.6 and 8.5 years, respectively. Both groups have 
evolved to improve at every application of rituximab; how-
ever, patients in TT group achieved better results than partici-
pants RWN, regarding HAQ-DI and DAS-28. In addition, during 
the first four applications of rituximab, more patients discon-
tinued the trial in RWN group compared to TT group, mainly 
due to an insufficient therapeutic response.
In general, rituximab in association with MTX proved to be 
as safe as MTX. Acute infusion reaction was the most common 
event and was more frequent in rituximab group compared to 
placebo, but only in the first infusion. Van Vollenhoven et al.44 
conducted a joint analysis of six RCTs (SERENE,30 DANCER,35 
REFLEX,37 SUNRISE,41 MIRROR43 and SIERRA45), including exten-
sions of open phase DANCER and REFLEX trials, and demon-
strated that the overall incidence was 359.6 adverse events 
per 100 patients-year (95% CI 354.4-364.9). The AE rate was 
higher after the first application, falling to 329.44 events per 
100 patient-years (320.59-338.53) after the second application, 
remaining stable until the subsequent five years of monitor-
ing. The most common event detected was an acute infusion 
reaction, occurring in 25% of participants. Other AEs occur-
ring in ≥ 10 % of the assessed population were infections, not 
including RA exacerbations. In this review, the mortality rate 
was 0.6 per 100 patient-years, and there were no deaths due 
to infusion reactions.
Loss of participants is critical in epidemiological trials, 
since the analysis, even if done by intention to treat, may be 
compromised. In the included RCTs, generally the losses did 
not exceed 20% and total loss and loss due to lack of efficacy 
were higher in placebo group compared to rituximab. The loss 
rates for EA were not different between groups.
Finckh et al.46 conducted a prospective cohort trial to as-
sess which subset of patients with RA and with anti-TNF 
failure obtain benefit with the exchange for rituximab versus 
exchange for another anti-TNF agent. Blom et al.47 evaluated a 
retrospective cohort of patients who had failed with two anti-
TNF agents and who were treated with a third anti-TNF drug 
(n = 64), or with rituximab (n = 90). These authors concluded 
that patients using rituximab obtained better results with 
respect to disease activity versus patients using anti-TNF 
agent.46,47 Both trials concluded that in case of failure with 
an anti-TNF treatment, the introduction of a biological agent 
with different mechanism of action, such as rituximab, would 
be the best conduct, increasing the efficacy of rituximab as 
third-line treatment.
Current guidelines from ACR for RA have established, as 
an alternative, the use of rituximab if the patient exhibits 
low activity associated with a poor prognosis, or moderate/
high activity.7 Current guidelines from EULAR recommend the 
use of rituximab only after a failure with anti-TNF, despite 
reiterating that the approval of rituximab for use as a second 
line option has been discussed in Europe.8 The results of this 
trial point to a possible benefit of rituximab for patients na-
ïve to anti-TNF. However, these findings should be evaluated 
with caution, since we could not find any RCT to evaluate the 
exchange by an anti-TNF, after failure of rituximab. The pos-
sibility of use of rituximab as a second line drug and of an 
anti-TNF as a third drug needs to be more deeply evaluated.
Data from IMAGE,27 DANCER,35 REFLEX,37 and SUNRISE41 
were used in subgroup analysis for seropositivity; we observed 
a trend towards greater efficacy of rituximab, compared to 
placebo, in the subgroup FR+ and/or anti-CCP+; however, the 
observed heterogeneity was high. In any case, we used the 
method of random effects, which may have underestimated 
differences between groups. The predictive value of assess-
ment of seropositivity needs to be further explored in future 
clinical trials, as well as the role of other biomarkers that may 
be useful for deciding on the best treatment to be used for 
each specific type of patient.
This RS has some limitations. The possibility of selection 
bias could not be excluded from most trials. Moreover, all in-
cluded trials were funded by pharmaceutical industry, which 
may have led to an overestimation of the results. Systematic 
reviews showed that industry-funded trials tend to show fa-
vourable results for its products, compared to not funded tri-
als.48,49
An inherent limitation of clinical trials, which is reflected 
in this RS, is the fact that they were conducted in carefully 
selected populations. Thus, the profile of patients does not 
reflect the reality, especially in relation to treatment adher-
ence (since these patients are followed more strictly) and to 
comorbidities, since they exclude patients with multiple co-
morbidities. Depression, hypertension and diabetes, for ex-
ample, negatively influence the quality of life, functionality, 
results and prognosis of subjects with RA.50
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Moreover, the analysis of which type of participant would 
be more benefited with the use of rituximab is not conclusive, 
since few trials within each group (MTX-naïve and anti-NPT-
naïve) were included. In general, the efficacy analyses were 
heterogeneous. Nevertheless, it was possible to assess the di-
rection of the effect that showed benefit with the use of ritux-
imab in all outcomes assessed.
Conclusion 
The trials included in this RS showed that rituximab is effec-
tive and safe compared to placebo for the treatment of RA, 
particularly in patients with a recent diagnosis. The effective-
ness was also observed both in naïve patients to anti-TNF as 
in those whose treatment with these agents had failed. The 
use of rituximab was well tolerated by all patient subtypes. 
More trials are needed to evaluate the role of RF and anti-CCP 
antibody in predicting success in the treatment of RA with 
rituximab, but there is indication that RF+ and anti-CCP+ pa-
tients exhibit a better response to this biological agent.
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